Sanuwave Health (NASDAQ:SNWV) Downgraded by Wall Street Zen to Hold

Sanuwave Health (NASDAQ:SNWV) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Sanuwave Health in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $54.00.

Sanuwave Health Trading Down 1.3%

Shares of SNWV opened at $18.61 on Friday. The stock has a market cap of $159.67 million, a P/E ratio of -116.31 and a beta of 1.32. Sanuwave Health has a 1 year low of $16.72 and a 1 year high of $46.58. The stock’s 50-day moving average price is $24.03 and its two-hundred day moving average price is $29.43.

Sanuwave Health (NASDAQ:SNWV) last announced its quarterly earnings results on Thursday, March 26th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.14). The company had revenue of $13.09 million during the quarter, compared to the consensus estimate of $13.23 million. Sanuwave Health had a net margin of 26.64% and a negative return on equity of 101.26%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SNWV. Goldman Sachs Group Inc. bought a new stake in shares of Sanuwave Health during the first quarter worth $337,000. Geode Capital Management LLC bought a new stake in Sanuwave Health in the 2nd quarter valued at $5,184,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Sanuwave Health in the 2nd quarter valued at $52,000. JPMorgan Chase & Co. acquired a new position in Sanuwave Health in the 2nd quarter worth $109,000. Finally, Legal & General Group Plc acquired a new position in Sanuwave Health in the 2nd quarter worth $26,000. Institutional investors and hedge funds own 42.53% of the company’s stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.